ORALLY DISINTEGRATING PHARMACEUTICAL COMPOSITION CONTAINING NEFOPAM, AND METHOD FOR PREPARATION THEREOF Russian patent published in 2025 - IPC A61K31/33 A61K31/395 A61K47/00 A61P25/04 

Abstract RU 2833481 C2

FIELD: medicine; pharmaceutics.

SUBSTANCE: group of inventions relates to pharmaceutical industry, namely to an orally disintegrating pharmaceutical composition containing nefopam, and a method for preparing it. Orally disintegrating pharmaceutical composition in the form of a tablet for rapid relief of acute pain contains nefopam and pharmaceutically acceptable inert excipients, wherein composition contains: pellets or granules having a taste-masking coating, wherein the pellets or granules contain 8.57 wt.% of nefopam hydrochloride, 27.71 wt.% of nonparelle seed crystals and 2.29 wt.% of hydroxypropyl methylcellulose, and wherein the taste-masking coating contains 2.19 wt.% of hydroxypropyl methylcellulose, 1.93 wt.% of colloidal silicon dioxide and 8.74 wt.% of poly(meth)acrylate polymer; 30.0 wt.% of microcrystalline cellulose; 10.0 wt.% of polyvinylpyrrolidone; 1.0 wt.% of colloidal silicon dioxide; 1.0 wt.% of magnesium stearate; 3.71 wt.% of mannitol; 2.00 wt.% of sweetener and 0.86 wt.% of flavoring agent, where % is given relative to total weight of composition. Method of producing said orally disintegrating pharmaceutical composition includes the following steps: obtaining pellets or granules of nefopam; taste masking of said pellets or granules; obtaining a mixture containing pharmaceutically acceptable inert excipients; mixing the mixture with pellets or granules of nefopam and its lubrication; and compressing the lubricated mixture to produce a tablet.

EFFECT: use of the group of inventions provides the creation of a composition characterized by rapid disintegration in the oral cavity and rapid relief of acute pain, wherein the time for complete disintegration of the composition is no more than 3 minutes at 37 ± 2 °C.

7 cl, 2 tbl, 2 ex

Similar patents RU2833481C2

Title Year Author Number
PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR 2007
  • Ambjul' Mikhaehl'
  • Bejer Jutta
  • Karreno-Gomes Begona
  • R'Jugger Kollin
  • Valazza Stiven
RU2487703C2
COMPOSITIONS CONTAINING WEAKLY BASIC DRUG SUBSTANCES, AND CONTROLLED-RELEASE DOSAGE FORMS 2009
  • Venkatesh Gopi
  • Lai Dzin-Vang
  • Stivens Filip Dzh.
RU2548748C2
COMPOSITIONS OF ORALLY DISPERSIBLE TABLETS CONTAINING COMBINATIONS OF HIGH- AND LOW-DOSE THERAPEUTIC AGENTS 2010
  • Venkatesh Gopi M.
  • Clevenger James
  • Gosselin Michael
  • Lai Jin-Wang
RU2554740C2
PAZOPANIB COMPOSITION 2012
  • Gossett Augustus Campbell
  • Richardson Helen
  • Williams Peter A.
RU2616500C2
PER ORALLY DECOMPOSING TABLET COMPOSITIONS, CONTAINING COMBINATIONS OF NON-OPIATE ANALGESICS 2010
  • Venkatesh Gopi M.
  • Clevenger James
  • Gosselin Michael
  • Lai Jin-Wang
RU2567032C2
COMPOSITION FOR TREATING MULTIPLE SCLEROSIS (VERSIONS) 2012
  • Fazylov Marat Feliksovich
RU2493845C1
COMPOSITION FOR TREATING MULTIPLE SCLEROSIS (VERSIONS) 2011
  • Fazylov Marat Feliksovich
RU2471482C1
IMMEDIATE-RELEASE SOLID DOSAGE FORM OF HYDROXYCHLOROQUINE AND METHOD FOR PRODUCING IT 2014
RU2580656C1
HARD DRUG FORM CONTAINING ACTIVE AGENT WITH DISGUISED TASTE 2007
  • Shobel' Aleksander Mark
  • Vangala Shjam Sundar Kumar Sarma
RU2437657C2
RASAGILINE COMPOSITIONS DEGRADING IN MOUTH CAVITY 2005
  • Patashnik Shulamit
  • Lajt Dehniella
  • Gilbert Adrian
RU2389482C2

RU 2 833 481 C2

Authors

Makhendra B. Chaudkhari

Dates

2025-01-22Published

2020-12-28Filed